HDAC6 and cancer: As the metastatic potential and HPV types of the two cancer cells are different (SiHa: established from situ tissue samples with HPV-16 positive; Caski: established from small intestinal mesenteric metastases with both HPV-16 and -18 positive), it seems that the sensitivity of such two cancer cells to AKT inhibitor-mediated activation of HDAC6 is also different.